JPMA Urges Drug Makers To Establish Pandemic Guidelines Amid Flu Infections
This article was originally published in PharmAsia News
Japan Pharmaceutical Manufacturers Association is urging member companies to establish flu pandemic guidelines. The drug makers' trade association found that out of 60 member companies that responded to a recent survey, 40 have established such guidelines, and JPMA urged quick action for the remaining companies. The recent domestic flu infections in Japan has prompted many drug companies to take measures such as reducing sales visits to hospitals. (Click here for more - Japanese language
You may also be interested in...
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.